Dupilumab versus omalizumab in patients with chronic rhinosinusitis with nasal polyps and coexisting asthma (EVEREST): a multicentre, randomised, double-blind, head-to-head phase 4 trial.
Saved in:
| Title: | Dupilumab versus omalizumab in patients with chronic rhinosinusitis with nasal polyps and coexisting asthma (EVEREST): a multicentre, randomised, double-blind, head-to-head phase 4 trial. |
|---|---|
| Authors: | De Corso E; Otorhinolaryngology-Head and Neck Surgery, A Gemelli Hospital Foundation IRCCS, Rome, Italy. Electronic address: eugenio.decorso@policlinicogemelli.it., Canonica GW; Personalized Medicine, Asthma and Allergy, Humanitas Research Hospital, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy., Heffler E; Personalized Medicine, Asthma and Allergy, Humanitas Research Hospital, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy., Springer M; Specialized Non-Public Health Care Facility Alergologia Plus, Allergy Diagnostics and Therapy Center, Poznań, Poland., Grzegorzek T; Department of Otorhinolaryngology, Angelius Provita Medical Center, Katowice, Poland., Viana M; Othorhinolaryngology Department, Hospital Pedro Hispano, Matosinhos, Portugal., Horváth Z; Otorhinolaryngology Department, Szent Imre University Teaching Hospital, Budapest, Hungary., Mullol J; Rhinology Unit & Smell Clinic, ENT Department, Hospital Clínic Barcelona, FRCB-IDIBAPS, Universitat de Barcelona, CIBERES, Barcelona, Spain., Gevaert P; Upper Airways Research Laboratory, Department of Head and Skin, Ghent University, Ghent, Belgium., Michel J; Aix Marseille University, APHM, CNRS, IUSTI, La Conception University Hospital, ENT-HNS Department, Marseille, France., Peters AT; Allergy-Immunology Division and the Sinus and Allergy Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA., Wagenmann M; Department of Otorhinolaryngology, Düsseldorf University Hospital (UKD), Düsseldorf, Germany., Zaghloul S; Sanofi, Morristown, NJ, USA., Zhang M; Sanofi, Morristown, NJ, USA., Corbett M; Sanofi, Morristown, NJ, USA., Nash S; Regeneron Pharmaceuticals, Tarrytown, NY, USA., Angello JT; Sanofi, Morristown, NJ, USA., Radwan A; Regeneron Pharmaceuticals, Uxbridge, UK., Deniz Y; Regeneron Pharmaceuticals, Tarrytown, NY, USA., Martin A; Sanofi, Cambridge, MA, USA., Hellings PW; University Hospitals Leuven, Leuven, Belgium. |
| Source: | The Lancet. Respiratory medicine [Lancet Respir Med] 2025 Dec; Vol. 13 (12), pp. 1067-1077. Date of Electronic Publication: 2025 Sep 28. |
| Publication Type: | Clinical Trial, Phase IV; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial |
| Journal Info: | Publisher: Elsevier Country of Publication: England NLM ID: 101605555 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2213-2619 (Electronic) Linking ISSN: 22132600 NLM ISO Abbreviation: Lancet Respir Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 41033334 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Dupilumab versus omalizumab in patients with chronic rhinosinusitis with nasal polyps and coexisting asthma (EVEREST): a multicentre, randomised, double-blind, head-to-head phase 4 trial. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22De+Corso+E%22">De Corso E</searchLink>; Otorhinolaryngology-Head and Neck Surgery, A Gemelli Hospital Foundation IRCCS, Rome, Italy. Electronic address: eugenio.decorso@policlinicogemelli.it.<br /><searchLink fieldCode="AU" term="%22Canonica+GW%22">Canonica GW</searchLink>; Personalized Medicine, Asthma and Allergy, Humanitas Research Hospital, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Heffler+E%22">Heffler E</searchLink>; Personalized Medicine, Asthma and Allergy, Humanitas Research Hospital, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Springer+M%22">Springer M</searchLink>; Specialized Non-Public Health Care Facility Alergologia Plus, Allergy Diagnostics and Therapy Center, Poznań, Poland.<br /><searchLink fieldCode="AU" term="%22Grzegorzek+T%22">Grzegorzek T</searchLink>; Department of Otorhinolaryngology, Angelius Provita Medical Center, Katowice, Poland.<br /><searchLink fieldCode="AU" term="%22Viana+M%22">Viana M</searchLink>; Othorhinolaryngology Department, Hospital Pedro Hispano, Matosinhos, Portugal.<br /><searchLink fieldCode="AU" term="%22Horváth+Z%22">Horváth Z</searchLink>; Otorhinolaryngology Department, Szent Imre University Teaching Hospital, Budapest, Hungary.<br /><searchLink fieldCode="AU" term="%22Mullol+J%22">Mullol J</searchLink>; Rhinology Unit & Smell Clinic, ENT Department, Hospital Clínic Barcelona, FRCB-IDIBAPS, Universitat de Barcelona, CIBERES, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Gevaert+P%22">Gevaert P</searchLink>; Upper Airways Research Laboratory, Department of Head and Skin, Ghent University, Ghent, Belgium.<br /><searchLink fieldCode="AU" term="%22Michel+J%22">Michel J</searchLink>; Aix Marseille University, APHM, CNRS, IUSTI, La Conception University Hospital, ENT-HNS Department, Marseille, France.<br /><searchLink fieldCode="AU" term="%22Peters+AT%22">Peters AT</searchLink>; Allergy-Immunology Division and the Sinus and Allergy Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.<br /><searchLink fieldCode="AU" term="%22Wagenmann+M%22">Wagenmann M</searchLink>; Department of Otorhinolaryngology, Düsseldorf University Hospital (UKD), Düsseldorf, Germany.<br /><searchLink fieldCode="AU" term="%22Zaghloul+S%22">Zaghloul S</searchLink>; Sanofi, Morristown, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Zhang+M%22">Zhang M</searchLink>; Sanofi, Morristown, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Corbett+M%22">Corbett M</searchLink>; Sanofi, Morristown, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Nash+S%22">Nash S</searchLink>; Regeneron Pharmaceuticals, Tarrytown, NY, USA.<br /><searchLink fieldCode="AU" term="%22Angello+JT%22">Angello JT</searchLink>; Sanofi, Morristown, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Radwan+A%22">Radwan A</searchLink>; Regeneron Pharmaceuticals, Uxbridge, UK.<br /><searchLink fieldCode="AU" term="%22Deniz+Y%22">Deniz Y</searchLink>; Regeneron Pharmaceuticals, Tarrytown, NY, USA.<br /><searchLink fieldCode="AU" term="%22Martin+A%22">Martin A</searchLink>; Sanofi, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Hellings+PW%22">Hellings PW</searchLink>; University Hospitals Leuven, Leuven, Belgium. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101605555%22">The Lancet. Respiratory medicine</searchLink> [Lancet Respir Med] 2025 Dec; Vol. 13 (12), pp. 1067-1077. <i>Date of Electronic Publication: </i>2025 Sep 28. – Name: TypePub Label: Publication Type Group: TypPub Data: Clinical Trial, Phase IV; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101605555 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2213-2619 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2222132600%22">22132600 </searchLink><i>NLM ISO Abbreviation: </i>Lancet Respir Med <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41033334 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/S2213-2600(25)00287-5 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 1067 Titles: – TitleFull: Dupilumab versus omalizumab in patients with chronic rhinosinusitis with nasal polyps and coexisting asthma (EVEREST): a multicentre, randomised, double-blind, head-to-head phase 4 trial. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: De Corso E – PersonEntity: Name: NameFull: Canonica GW – PersonEntity: Name: NameFull: Heffler E – PersonEntity: Name: NameFull: Springer M – PersonEntity: Name: NameFull: Grzegorzek T – PersonEntity: Name: NameFull: Viana M – PersonEntity: Name: NameFull: Horváth Z – PersonEntity: Name: NameFull: Mullol J – PersonEntity: Name: NameFull: Gevaert P – PersonEntity: Name: NameFull: Michel J – PersonEntity: Name: NameFull: Peters AT – PersonEntity: Name: NameFull: Wagenmann M – PersonEntity: Name: NameFull: Zaghloul S – PersonEntity: Name: NameFull: Zhang M – PersonEntity: Name: NameFull: Corbett M – PersonEntity: Name: NameFull: Nash S – PersonEntity: Name: NameFull: Angello JT – PersonEntity: Name: NameFull: Radwan A – PersonEntity: Name: NameFull: Deniz Y – PersonEntity: Name: NameFull: Martin A – PersonEntity: Name: NameFull: Hellings PW IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 12 Text: 2025 Dec Type: published Y: 2025 Identifiers: – Type: issn-electronic Value: 2213-2619 Numbering: – Type: volume Value: 13 – Type: issue Value: 12 Titles: – TitleFull: The Lancet. Respiratory medicine Type: main |
| ResultId | 1 |
